[go: up one dir, main page]

FI971127A0 - 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen - Google Patents

2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen

Info

Publication number
FI971127A0
FI971127A0 FI971127A FI971127A FI971127A0 FI 971127 A0 FI971127 A0 FI 971127A0 FI 971127 A FI971127 A FI 971127A FI 971127 A FI971127 A FI 971127A FI 971127 A0 FI971127 A0 FI 971127A0
Authority
FI
Finland
Prior art keywords
pct
oxide
diamino
pyrimidine
buildup
Prior art date
Application number
FI971127A
Other languages
English (en)
Swedish (sv)
Other versions
FI971127L (fi
FI971127A7 (fi
Inventor
Yann Mahe
Lionel Breton
Jean-Baptiste Galey
Bruno Bernard
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Publication of FI971127L publication Critical patent/FI971127L/fi
Publication of FI971127A0 publication Critical patent/FI971127A0/fi
Publication of FI971127A7 publication Critical patent/FI971127A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FI971127A 1994-09-19 1995-09-19 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollagee nin kypsymis- ja rakentumishäiriöiden hoitamiseen FI971127A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411133A FR2724561B1 (fr) 1994-09-19 1994-09-19 Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene
PCT/FR1995/001197 WO1996009048A1 (fr) 1994-09-19 1995-09-19 Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene

Publications (3)

Publication Number Publication Date
FI971127L FI971127L (fi) 1997-03-18
FI971127A0 true FI971127A0 (fi) 1997-03-18
FI971127A7 FI971127A7 (fi) 1997-03-18

Family

ID=9467049

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971127A FI971127A7 (fi) 1994-09-19 1995-09-19 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollagee nin kypsymis- ja rakentumishäiriöiden hoitamiseen

Country Status (22)

Country Link
US (1) US5846552A (fi)
EP (1) EP0783307B1 (fi)
JP (1) JP2945482B2 (fi)
KR (1) KR100250939B1 (fi)
CN (1) CN1070702C (fi)
AT (1) ATE213414T1 (fi)
AU (1) AU691336B2 (fi)
BR (1) BR9508841A (fi)
CA (1) CA2199995C (fi)
CZ (1) CZ284476B6 (fi)
DE (1) DE69525539T2 (fi)
DK (1) DK0783307T3 (fi)
ES (1) ES2171550T3 (fi)
FI (1) FI971127A7 (fi)
FR (1) FR2724561B1 (fi)
HU (1) HU223143B1 (fi)
MX (1) MX9701996A (fi)
NO (1) NO311784B1 (fi)
PL (1) PL186385B1 (fi)
PT (1) PT783307E (fi)
RU (1) RU2153874C2 (fi)
WO (1) WO1996009048A1 (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875781B1 (en) * 1997-04-30 2005-08-17 JSR Corporation Liquid crystal alignment layer, production method for the same, and liquid crystal display device comprising the same
US7763587B2 (en) 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
FR2871688B1 (fr) 2004-06-16 2008-05-16 Oreal Procede pour favoriser la penetration d'un actif et composition permettant sa mise en oeuvre
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
FR2902324B1 (fr) * 2006-06-20 2009-04-03 Oreal Utilisation d'acide ellagique pour le traitement de la canitie
EP1897533A1 (en) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
WO2010013182A1 (en) 2008-07-29 2010-02-04 L'oreal Cosmetic use of microorganism(s) for the treatment of scalp disorders
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
CN104398418A (zh) * 2014-11-06 2015-03-11 陈爱华 一种防脱发护发素
FR3130153A1 (fr) 2021-12-15 2023-06-16 L'oreal Utilisation d’au moins un dérivé de pyrimidine 3-oxyde pour renforcer la fonction barrière de la peau
FR3149509A1 (fr) 2023-06-08 2024-12-13 L'oreal Procédé utilisant la radiofréquence et une composition cosmétique
FR3150431A1 (fr) * 2023-06-30 2025-01-03 L'oreal Utilisation d’au moins un dérivé de pyrimidine 3-oxyde pour prévenir et/ou traiter les signes cutanés du vieillissement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049902A3 (en) * 1980-10-15 1982-09-01 Teijin Limited Novel thiazolo(3,2-a)pyrimidines, derivatives thereof, processes for production thereof, and pharmaceutical use thereof
FR2644460A1 (fr) * 1989-03-16 1990-09-21 Oreal Esters retinoiques de d-desosamine, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
EP0548883A1 (de) * 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PT783307E (pt) 2002-07-31
CZ84297A3 (en) 1997-08-13
HU223143B1 (hu) 2004-03-29
AU3476595A (en) 1996-04-09
WO1996009048A1 (fr) 1996-03-28
NO311784B1 (no) 2002-01-28
CZ284476B6 (cs) 1998-12-16
ES2171550T3 (es) 2002-09-16
US5846552A (en) 1998-12-08
DK0783307T3 (da) 2002-06-03
RU2153874C2 (ru) 2000-08-10
ATE213414T1 (de) 2002-03-15
KR100250939B1 (ko) 2000-05-01
MX9701996A (es) 1997-06-28
CA2199995A1 (fr) 1996-03-28
FI971127L (fi) 1997-03-18
EP0783307B1 (fr) 2002-02-20
EP0783307A1 (fr) 1997-07-16
CN1070702C (zh) 2001-09-12
PL186385B1 (pl) 2004-01-30
PL319279A1 (en) 1997-08-04
CA2199995C (fr) 2002-01-15
FR2724561B1 (fr) 1996-12-13
JPH10506886A (ja) 1998-07-07
NO971182D0 (no) 1997-03-14
FI971127A7 (fi) 1997-03-18
CN1159755A (zh) 1997-09-17
AU691336B2 (en) 1998-05-14
NO971182L (no) 1997-05-14
HUT76796A (en) 1997-11-28
DE69525539T2 (de) 2002-09-26
DE69525539D1 (de) 2002-03-28
KR970705998A (ko) 1997-11-03
BR9508841A (pt) 1999-05-04
JP2945482B2 (ja) 1999-09-06
FR2724561A1 (fr) 1996-03-22

Similar Documents

Publication Publication Date Title
FI971127A0 (fi) 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
DE69524944D1 (de) Methode zum herstellen eines dentalproduktes
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
SE9502219D0 (sv) Novel medical use
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
EA199800953A1 (ru) Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
MX9800686A (es) Nueva proteina hmw humana mp52s.